GleamWall
中文EN

EDSA Edesa Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—

Leverage & solvency

Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue——
R&D expense$3.67M$2.88M
SG&A expense$4.24M$4.13M
Operating income-$7.91M-$7.01M
Pretax income-$7.18M-$6.17M
Income tax$800$800
Net income-$7.19M-$6.17M
EBITDA-$7.79M-$6.83M
EPS (basic)-1.27-1.93
EPS (diluted)——
Balance sheet
Cash & equivalents$10.79M$1.04M
Current assets$11.51M$1.68M
PP&E, net—$0
Intangibles$1.98M$2.08M
Total assets$13.53M$3.81M
Current liabilities$1.08M$1.83M
Total liabilities$1.08M$1.83M
Shareholders' equity$12.45M$1.98M
Shares outstanding7.14M3.25M
Cash flow statement
Operating cash flow-$7.32M-$4.89M
Financing cash flow$17.03M$592,031
Depreciation & amortization$119,273$186,049
Stock-based compensation$729,642$537,492

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.